(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Dry Eye

Drug Information

Target Indication

Dry Eye

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

ABT

ABBOTT LABORATORIES

Related Pipeline

Kidney Disease

Chronic Low Back Pain

Mixed Dyslipidemia

Chronic Kidney Disease on Hemodialysis

Moderate to Severe Chronic, Non-malignant Pain

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts